Medpace (MEDP)
(Delayed Data from NSDQ)
$356.40 USD
+13.51 (3.94%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $357.00 +0.60 (0.17%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$356.40 USD
+13.51 (3.94%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $357.00 +0.60 (0.17%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum B VGM
Zacks News
Are Medical Stocks Lagging Immunocore (IMCR) This Year?
by Zacks Equity Research
Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Medpace (MEDP) have performed compared to their sector so far this year.
Did Midterm Voters Help Stocks Out?
by John Blank
They usually do. Markets don't like political uncertainty.
Humana's (HUM) Arm to Aid Senior Care, 2023 Expansion on Track
by Zacks Equity Research
Humana's (HUM) CenterWell brand plans to open centers in untapped markets as well as dig deeper into the existing regions offering enhanced primary care services to the nation's senior citizens.
National Vision (EYE) Q3 Earnings Top Mark, Margins Down
by Zacks Equity Research
National Vision (EYE) is facing demand headwinds across its network of stores due to the constraints on eye exam capacity.
Globus Medical (GMED) Q3 Earnings Miss Estimates, EPS View Cut
by Zacks Equity Research
Internationally, Globus Medical (GMED) reports double-digit growth in most markets, with the U.K., Australia, Brazil, India and Poland registering more than 40% growth.
Cardiovascular Systems (CSII) Q1 Earnings Miss, Revenues Top
by Zacks Equity Research
The launch of the Scoreflex scoring balloon receives a positive response and generates over $1.7 million in sales during the first quarter for Cardiovascular Systems (CSII).
Haemonetics (HAE) Q2 Earnings Beat Estimates, 2023 View Up
by Zacks Equity Research
Under the Hospital segment, despite continued macroeconomic, Haemonetics (HAE) meaningfully grows revenues and market share.
BD (BDX) Q4 Earnings and Revenues Beat Estimates, Margins Up
by Zacks Equity Research
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal fourth quarter.
QIAGEN's (QGEN) Q3 Earnings Top Estimates, 2022 View Up
by Zacks Equity Research
The ongoing double-digit sales growth in the non-COVID product portfolio, a high level of profitability and strong cash flow are the major upsides for QIAGEN (QGEN).
STERIS (STE) Q2 Earnings Miss Estimates, Margins Increase
by Zacks Equity Research
Barring AST, poor reported revenue performance across three of STERIS' (STE) operating segments poses concerns.
Surmodics (SRDX) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Surmodics (SRDX) reports a solid fiscal fourth quarter top line on the back of robust Medical Device revenues.
Masimo (MASI) Q3 Earnings Top Estimates, 2022 View Revised
by Zacks Equity Research
Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q3 sales.
Insulet (PODD) Q3 Earnings Beat Estimates, '22 Sales View Up
by Zacks Equity Research
Insulet's (PODD) performance benefits from record quarterly U.S. and Total Omnipod new customer starts.
Syneos Health (SYNH) Q3 Earnings Miss Estimates, '22 View Cut
by Zacks Equity Research
Syneos Health (SYNH) Q3 revenues are below the guidance primarily due to the impact of lower net new business awards, delays in backlog conversion and customer delays in its FSP business.
OPKO Health (OPK) Q3 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
OPKO Health's (OPK) third-quarter results reflect dismal segmental performances.
PerkinElmer (PKI) Q3 Earnings Top, Revenues Decline Y/Y
by Zacks Equity Research
PerkinElmer's (PKI) third-quarter results benefit from the solid performance of the Discover & Analytics Solutions business, which was more than offset by lower COVID-related sales.
Shockwave Medical (SWAV) Beats on Q3 Earnings & Revenues
by Zacks Equity Research
Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and expansion in gross margin.
PacBio's (PACB) Q3 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
PacBio (PACB) witnesses strength in Service and other revenues, along with robust consumable sales, in the third quarter.
Bruker (BRKR) Q3 Earnings Beat Estimates, '22 Sales View Down
by Zacks Equity Research
Despite ongoing macroeconomic headwinds, Bruker (BRKR) registers strong demand for differentiated high-value scientific instruments and life science solutions.
Omnicell (OMCL) Q3 Earnings Beat Estimates, Guidance Cut
by Zacks Equity Research
Rise in operating expenses result in an operating loss in Q3 for Omnicell (OMCL), placing significant pressure on the bottom line.
Tandem Diabetes (TNDM) Q3 Earnings Miss, Sales View Cut
by Zacks Equity Research
Tandem Diabetes (TNDM) defers $0.6 million of United States pump sales as a result of Tandem Choice.
Elections to Clear Up Uncertainty: Zacks NOV Strategy
by John Blank
Tuesday's U.S. midterm elections should clear up recent political uncertainty. Stock markets never like any flavor of uncertainty. How should eager investors play fresh bullish sentiment?
Avanos (AVNS) Q3 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Avanos' (AVNS) third-quarter 2022 results reflect strength in the Pain Management segment.
Cardinal Health (CAH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cardinal Health's (CAH) fiscal first-quarter results benefit from the solid performance of the Pharmaceutical segment.
Exact Sciences (EXAS) Q3 Earnings Top Estimates, Margin Falls
by Zacks Equity Research
Exact Sciences (EXAS) registers robust revenues from the Screening and Precision Oncology segments in Q3.